Silence Therapeutics Plc - American Depository Share (SLN)

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.

What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025.

Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.

Silence Therapeutics just reported results for the second quarter of 2024.

These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.

It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.

Silence Therapeutics just reported results for the first quarter of 2024.

Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.

With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.

Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday.

Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of SLN501 following the completion of the phase 1 clinical trial.

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.